Active surveillance, genomic testing, immunotherapy and advanced disease therapies have all reached a level of maturity and acceptance over the past five years. This session will review how these developments have changed the prostate cancer treatment paradigm for high-risk men with an assessment on the potential impact for reducing the prostate cancer racial disparity.